WOBURN, Mass., Sept. 30 /PRNewswire/ -- The Center for Business Intelligence (CBI) recently announced the full agenda for their life sciences Commercialization and Market Access Congress (CMAC 2010). CBI, a renowned leader in the commercialization arena, has combined four of their most respected events - Product Launch, Product Pricing, Early-Stage Commercialization and Specialty Drug Commercialization - into one comprehensive agenda with extensive coverage of the evolving dynamics impacting market access and commercialization. The Congress takes place December 8-9, 2010 in Orlando, FL.
CMAC 2010 combines both a strategic view of current events impacting commercialization with targeted breakouts and tracks, addressing models for commercialization that respond to the new economic landscape while accounting for the changing relationship between patients, physicians and payers. A keynote panel discussion on "Changes in the Market Access Landscape" will be a highlight at this timely event.
CMAC's speaker faculty includes more than 30 of the country's leading experts from the most innovative biotechnology and medical device companies to the most established pharmaceutical companies including Abbott, AstraZeneca, Bayer HealthCare Pharmaceuticals, Cephalon, Daiichi Sankyo, Endo Pharmaceuticals, Medtronic, Mannkind Corporation, Merck, Pfizer, Schering-Plough, Shire, Talecris Biotherapeutics and many more.
CMAC 2010 is the industry's only opportunity to participate in an executive-level exchange addressing the overarching product development and launch environment, as well as tactical approaches for pricing, reimbursement, product launch, commercial strategy, branding, managed care and HEOR. For more information on the conference or to view the entire agenda, please visit http://www.cmac2010.com.
A subsidiary of Advanstar Co
|SOURCE Center for Business Intelligence|
Copyright©2010 PR Newswire.
All rights reserved